Transthyretin (TTR) stabiliser
Acoramidis
Brand names: Beyonttra
Adult dose
Dose: 800 mg BD (per SmPC)
Route: Oral
Frequency: Twice daily
Clinical pearls
- Wild-type or hereditary ATTR cardiomyopathy; specialist initiation; may displace thyroxine and lower TTR levels
Contraindications
- Hypersensitivity
Side effects
- Diarrhoea
- Abdominal pain
- Reduced thyroxine-binding (interpret thyroid tests with care)
Interactions
- Limited; refer to SmPC
Monitoring
- NT-proBNP, NYHA class
- TFTs interpretation
Reference: BNF; ESC HF 2023 update; SmPC Beyonttra. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines